Toll- Like Receptor Agonist Pipeline Analysis Demonstrates Novel 60+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

February 16 23:08 2023
Toll- Like Receptor Agonist Pipeline Analysis Demonstrates Novel 60+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight’s, “Toll- Like Receptor Agonist Pipeline Insight, 2023,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Toll- Like Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including Toll-Like Receptor Agonist clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Toll- Like Receptor Agonist Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Toll- Like Receptor Agonist NDA approvals (if any), and product development activities comprising the technology, Toll- Like Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Toll-Like Receptor Agonist Pipeline Report

 

  • DelveInsight’s Toll-Like Receptor Agonist Pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Toll- Like Receptor Agonist treatment.

 

  • The leading Toll- Like Receptor Agonist Pipeline Companies includes InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and others.

 

  • Promising Toll- Like Receptor Agonist Pipeline Therapies includes P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod,  BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others

 

  • The Toll- Like Receptor Agonist companies and academics are working to assess challenges and seek opportunities that could influence Toll- Like Receptor Agonist R&D. The Toll- Like Receptor Agonist pipeline therapies under development are focused on novel approaches to treat/improve Toll- Like Receptor Agonist.

 

To explore more information on the latest breakthroughs in the Toll-Like Receptor Agonist Pipeline treatment landscape of the report, click here @ Toll-Like Receptor Agonist Pipeline Outlook

 

Toll- Like Receptor Agonist Overview

Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. TLR1, -2, -4, -5, -6, and -10 are expressed on the cell surface, whereas TLR3, -7, -8, and -9 are situated on endosomal membranes within the cell [5, 9, 10]. TLR1 and TLR2 can heterodimerize to recognize a variety of bacterial lipid structures and cell wall components, such as triacylated lipoproteins, lipoteichoic acid, and β-glucans. Engaging TLRs through their specific ligands leads to activation of the innate immune system and secondarily priming of the adaptive immune system. Because of these unique properties, TLR agonists have been investigated as immunotherapy in cancer treatment for many years, but in recent years there has also been growing interest in the use of TLR agonists in the context of human immunodeficiency virus type 1 (HIV-1) cure research.

 

Latest Developmental Activities in the Toll-Like Receptor Agonist Treatment Landscape

  • In February 2022, Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system without causing inflammation.

 

  • Pattern’s lead product, P2PAR-100, is an immunotherapeutic that activates innate immune cells to kill cancer cells and safely activates an efficacious innate and adaptive immune response.

 

For further information, refer to the detailed Toll- Like Receptor Agonist Unmet Needs, Toll- Like Receptor Agonist Market Drivers, and Toll- Like Receptor Agonist Market Barriers, click here for Toll- Like Receptor Agonist Ongoing Clinical Trial Analysis

 

Toll- Like Receptor Agonist Emerging Drugs Profile

 

  • Cobitolimod: InDex Pharmaceuticals

Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod met the primary endpoint in the Phase IIb study CONDUCT and demonstrated an outstanding combination of efficacy and safety. In March 2021, InDex Pharmaceuticals announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the Phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

 

  • Tilsotolimod: Idera Pharmaceuticals

Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Intratumoral injection of tilsotolimod has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the FDA and is being evaluated in multiple tumor types and in combination with multiple checkpoint inhibitors. In March 2021, Idera Pharmaceuticals announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).

 

Toll- Like Receptor Agonist Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Toll- Like Receptor Agonist. The companies which have their Toll- Like Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

 

Request a sample and discover the recent advances in Toll- Like Receptor Agonist Ongoing Clinical Trial Analysis and Medications, click here @ Toll- Like Receptor Agonist Treatment Landscape

 

Scope of the Toll- Like Receptor Agonist Pipeline Report

 

  • Coverage- Global

 

  • Toll- Like Receptor Agonist Companies- InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and others.

 

  • Toll- Like Receptor Agonist Pipeline Therapies- P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod,  BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others

 

  • Toll- Like Receptor Agonist Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

 

Dive deep into rich insights for drugs for Toll- Like Receptor Agonist Market Drivers and Toll- Like Receptor Agonist Market Barriers, click here @ Toll- Like Receptor Agonist Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Toll- Like Receptor Agonist: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Cobitolimod: InDex Pharmaceuticals
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Cavrotolimod: Exicure
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. BDB-018: Seven and Eight Biopharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Preclinical stage products 
  16. BDB-030: Seven and Eight Biopharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Toll- Like Receptor Agonist Key Companies
  20. Toll- Like Receptor Agonist Key Products
  21. Toll- Like Receptor Agonist- Unmet Needs
  22. Toll- Like Receptor Agonist- Market Drivers and Barriers
  23. Toll- Like Receptor Agonist- Future Perspectives and Conclusion
  24. Toll- Like Receptor Agonist Analyst Views
  25. Toll- Like Receptor Agonist Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Toll- Like Receptor Agonist Mergers and acquisitions, Toll- Like Receptor Agonist Licensing Activities @ Toll- Like Receptor Agonist Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

view more articles

About Article Author